Ozempic face and loose skin: what the research actually shows

What does "Ozempic face" mean?

The phrase comes from the media, not from medicine. It describes a face that looks hollow, thinner or older after fast weight loss on a GLP-1 medicine such as semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro). People describe sunken cheeks, hollow eyes and sagging skin around the jaw and neck.

It is not a medical diagnosis. A 2026 systematic review put it plainly: these changes are not recognized as a distinct clinical entity and may overlap with what happens after any rapid or large weight loss.³ In other words, the medicine's name is attached because it is popular, not because researchers have shown the face changes differently on it than with weight loss by other means.

Why would a face change with weight loss?

The face has several pads of fat, some just under the skin and some deeper. A 2026 dermatology review from Mayo Clinic authors describes the changes as volume deflation, skin laxity and loss of structural support. It points to fat in the deeper layers of the skin, bone changes with age and muscle loss as possible contributors.⁴ Age matters: skin that is already less elastic may not shrink back as well after the fat under it goes.

How much facial volume do people lose? The imaging study

The first study to measure this directly came from Vanderbilt University in 2025. Researchers searched hospital records for patients who had a GLP-1 prescription and also happened to have head or neck CT or MRI scans both before and after starting it. Twenty patients qualified.¹

The median age was 54. Superficial fat fell by a median of 11% and deep fat by 7%, though the deep fat results varied widely between people. More weight loss went with more loss of superficial facial fat, but not deep fat.¹

This is a small, retrospective study from one hospital, with no comparison group of people who lost the same weight without medication. So it shows that facial fat goes down with weight loss on these drugs. It cannot show that GLP-1 medicines affect the face more than any other way of losing the same amount of weight.

What else has been published?

The 2025 systematic review found 23 plastic surgery articles on GLP-1 medicines. It also found that online searches for "Ozempic face" rose alongside searches for "face filler" and "plastic surgeons".² The clinician survey reported a mean increase of 137% from 2023 to 2024 in the number of their patients on GLP-1 medicines. Two of its authors work for a company that makes facial fillers, so read it as a picture of what clinicians report seeing, not as measured data.⁵

The 2026 review of treatments looked for any study testing a fix for these changes. All four it found lacked a comparison group, so it concluded that no conclusions could be drawn about whether any treatment works.³ We do not recommend any product or procedure here.

Does GLP-1 weight loss cause loose skin on the body?

There are no trial data on loose skin with semaglutide or tirzepatide. The closest evidence comes from bariatric surgery, where people also lose a lot of weight over months. In a Swedish survey of people who had bariatric surgery at one hospital, the most commonly reported site of excess skin was the upper arms in women (91%) and the abdomen in men (78%). Women reported more problems and discomfort from excess skin than men, and the amount of excess skin tracked closely with how much discomfort people felt.⁶

Weight loss in the main GLP-1 trials is usually smaller than after surgery, so these numbers may overstate what people on medication experience. How much loose skin someone has likely depends on how much they lose, their age and their skin, but this has not been studied well in people taking GLP-1 medicines.

Is Ozempic face on the drug label?

No. We checked the current US prescribing information for Wegovy (revised June 2026) and Zepbound (revised August 2026). Neither lists facial volume loss, sagging or loose skin as an adverse reaction.⁸ Both do list hair loss in section 6.1 and say it was associated with weight reduction:

• Wegovy: hair loss in 3.3% of people on 2.4 mg vs 1% on placebo in pooled adult trials, and in 5.8% of people on the 7.2 mg dose.⁸
• Zepbound: hair loss in 7.1% of women vs 0.5% of men on tirzepatide in pooled trials.⁸

The Wegovy label also lists dysesthesia, a group of altered skin sensations such as sensitive or burning skin, which became more common at higher doses.⁸ That is about how skin feels, not how it looks. For more, see GLP-1 and hair loss.

Do protein and strength training help?

No study has tested whether protein or exercise prevents "Ozempic face" or loose skin. What guidance does address is lean mass, meaning muscle and other non-fat tissue, which is also lost during weight loss. A 2025 joint advisory from four US nutrition and obesity societies notes that targets of 1.2–1.6 g of protein per kg per day have been proposed during active weight loss. It says GLP-1 medicines should be paired with a structured exercise program that includes strength training at least three times a week, to preserve muscle and bone.⁷

The same advisory lists skin flakiness or itching and excessive hair loss among possible signs of a nutrient deficiency, which can happen when appetite is very low.⁷ Read more in how much protein you need on a GLP-1 and GLP-1 and strength training.